Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 4, 2010, Pages 1717-1725

  Liou, Jyh Ming ^a,b   Shun, Chia Tung ^a   Liang, Jin Tung ^a,c   Chiu, Han Mo ^a   Chen, Mei Jyh ^a   Chen, Chien Chuan ^a   Wang, Hsiu Po ^a   Wu, Ming Shiang ^a   Lin, Jaw Town ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; DNA; RNA; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE PAYMENT; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; UNIVERSITY HOSPITAL; AGED; BIOSYNTHESIS; BLOOD; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; GENOME IMPRINTING; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

AGED; COLONIC POLYPS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA; FEMALE; GENOMIC IMPRINTING; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR II; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RNA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951641606     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2668     Document Type: Article

References (46)

1. Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK; Asia Pacific Working Group on Colorectal Cancer 2008 Asia Pacific consensus recommendations for colorectal cancer screening. Gut 57:1166-1176
2. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ; American Cancer Society Colorectal Cancer Advisory Group;US Multi-Society Task Force; American College of Radiology Colon Cancer Committee 2008 Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi- Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134:1570-1595
3. Liou JM, Lin JT, Huang SP, Chiu HM, Wang HP, Lee YC, Lin JW, Shun CT, Liang JT, Wu MS 2007 Screening for colorectal cancer in average-risk Chinese population using a mixed strategy with sigmoidoscopy and colonoscopy. Dis Colon Rectum 50:630-640
4. Min/+ mice. Cancer Res 60:1070-1076
5. Renehan AG, Painter JE, O'Halloran D, Atkin WS, Potten CS, O'Dwyer ST, ShaletSM2000 Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 85:3402-3408
6. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G 1994 Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57:491-497
7. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C 1999 IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83:15-17
8. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST 2000 Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein- 2 in patients with colorectal cancer. Br J Cancer 83:1344-1350
9. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G 2008 Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14:1065-1072
10. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC 2005 Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102:7677-7682 (Pubitemid 40741030)
11. Miraki-Moud F, Jenkins PJ, Fairclough PD, Jordan S, Bustin SA, Jones AM, Lowe DG, Monson JP, Grossman AB, Besser GM, Camacho-Hübner C 2001 Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly. Clin Endocrinol (Oxf) 54:499-508
12. Baron-Hay S, Boyle F, Ferrier A, Scott C 2004 Elevated serum insulin- like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 10:1796-1806
13. Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP 2008 Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Res 68:8788-8795
14. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, Mayer D 2005 Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 36:1186-1196 (Pubitemid 41540395)
15. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Risch HA, Puopolo M, Yu H 2006 The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-α expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 12:1208-1214
16. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N, Cellerino R 2008 Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 19:1293-1298
17. Peters G, Gongoll S, Langner C, Mengel M, Piso P, Klempnauer J, Rüschoff J, Kreipe H, von Wasielewski R 2003 IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch 443:139-145
18. Zhao R, Berho M, Nogueras J, Sands D, Weiss E, Wexner S, Giardiello FM, Cruz-Correa M 2005Positive correlation of insulin-like growth factor-II with proliferating cell index in patients with colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 14:1819-1822
19. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W 2007 Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104:11736-11741 (Pubitemid 47175082)
20. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemistö A, Kavanagh JJ, Lee JH, Zhang W 2005 Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 4:7
21. Dawczynski K, Steinbach D, Wittig S, Pfaffendorf N, Kauf E, Zintl F 2008 Expression of components of the IGF axis in childhood acute myelogenous leukemia. Pediatr Blood Cancer 50:24-28
22. Vorwerk P, Mohnike K, Wex H, Röhl FW, Zimmermann M, Blum WF, Mittler U 2005 Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 90:3022-3027
23. Woodson K, Flood A, Green L, Tangrea JA, Hanson J, Cash B, Schatzkin A, Schoenfeld P 2004 Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst 96:407-410 (Pubitemid 38351303)
24. Tang SH, Yang DH, Huang W, Zhou HK, Lu XH, Ye G 2006 Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res 12:4171-4177
25. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg AP 1998 Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 91:3144-3147
26. Liou JM, Wu MS, Lin JT, Wang HP, Huang SP, Chiu HM, Lee YC, Lin YB, Shun CT, Liang JT 2007 Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancer. Eur J Cancer 43:1276-1282
27. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP 1998 Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 4:1276-1280 (Pubitemid 28512108)
28. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A1993 Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77:229-233
29. Eiseman JL, Guo J, Ramanathan RK, Belani CP, Solit DB, Scher HI, Ivy SP, Zuhowski EG, Egorin MJ 2007 Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clin Cancer Res 13:2121-2127
30. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M 2008 Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14:6944-6954
31. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E 2001 Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 61:8601-8610
32. Diehl D, Hessel E, Oesterle D, Renner-Müller I, Elmlinger M, Langhammer M, Göttlicher M, Wolf E, Lahm H, Hoeflich A 2009 IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer 124:2220-2225
33. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E 2000 Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592-1600
34. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, Biessy C, Tjønneland A, Olsen A, Overvad K, Grønbaek H, Clavel- Chapelon F, Boutron-Ruault MC, Linseisen J, Boeing H, Pischon T, Trichopoulos D, Oikonomou E, Trichopoulou A, Panico S, Vineis P, Berrino F, Tumino R, Masala G, Peters PH, van Gils CH, Buenode- Mesquita HB, Ocké MC, Lund E, Mendez MA, Tormo MJ, Barricarte A, Martínez-García C, Dorronsoro M, Quirós JR, Hallmans G, Palmqvist R, Berglund G, Manjer J, Key T, Allen NE, Bingham S, Khaw KT, Cust A, Kaaks R 2007 Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer121:368-376 (Pubitemid 46917707)
35. McDonald KL, O'Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook RJ, Biggs MT, Little NS, Teo C, Stone G, Robinson BG 2007IQGAP1and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66:405-417
36. Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C, Disis ML 2008 Insulin-like growth factorbinding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68:8400-8409
37. Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT 2003 Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol 91:486-493
38. Han JY, Choi BG, Choi JY, Lee SY, Ju SY 2006 The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 54:227-234
39. Singer CF, Mogg M, Koestler W, Pacher M, Marton E, Kubista E, Schreiber M 2004 Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clin Cancer Res 10:4003-4009
40. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT 2007 Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13:2054-2060
41. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M 2008 Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 14:8263-8269
42. Michell NP, Langman MJ, Eggo MC 1997 Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 76:60-66
43. Kaneda A, Wang CJ, Cheong R, Timp W, Onyango P, Wen B, Iacobuzio-Donahue CA, Ohlsson R, Andraos R, Pearson MA, Sharov AA, Longo DL, Ko MS, Levchenko A, Feinberg AP 2007 Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF-II to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA 104: 20926-20931
44. Miyamoto S, Nakamura M, Shitara K, Nakamura K, Ohki Y, Ishii G, Goya M, Kodama K, Sangai T, Maeda H, Shi-Chuang Z, Chiba T, Ochiai A 2005 Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 11:3494-3502
45. Cui H 2007 Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers 23:105-112 (Pubitemid 46333644)
46. Arafat AM, Weickert MO, Frystyk J, Spranger J, Schöfl C, Möhlig M, Pfeiffer AF 2009 The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 94:5093-5101